

1 **Integrating bulk and single-cell RNA sequencing reveals *SH3D21***
2 **promotes hepatocellular carcinoma progression by activating the**
3 **PI3K/AKT/mTOR pathway**

4 **Wangxia Tong¹, Tao Lu², Li Liu¹, Rong Liu¹, Jibing Chen^{3*}, Ning Luo^{4*}**

5 ¹ Department of Hepatology, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine,
6 Nanning, Guangxi, China.

7 ² Department of hepatobiliary surgery, Ruikang Hospital Affiliated to Guangxi University of Chinese
8 Medicine, Nanning, Guangxi, China.

9 ³ Center for Translational Medicine of Integrated Traditional Chinese and Western Medicine, Ruikang
10 Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, Guangxi, China.

11 ⁴ Department of Neurology, RuiKang Hospital Affiliated to Guangxi University of Chinese Medicine,
12 Nanning, Guangxi, China.

13 *Corresponding author

14 Ning Luo

15 E-mail: ln760320@163.com

16 [†] Wangxia Tong and Tao Lu contributed equally to this work.

17 & Jibing Chen and Ning Luo contributed equally to this work.

18 **Abstract**

19 As a novel genetic biomarker, the potential role of *SH3D21* in hepatocellular carcinoma remains unclear.

20 Here, we decipher the expression and function of *SH3D21* in human hepatocellular carcinoma. The

21 expression level and clinical significance of *SH3D21* in hepatocellular carcinoma patients, the

22 relationship between *SH3D21* and the features of tumor microenvironment (TME) and role of *SH3D21*

23 in promoting hepatocellular carcinoma progression were analyzed based on the bulk samples obtained

24 from The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 databases. Single-cell sequencing samples from Gene Expression Omnibus (GEO) database were
26 employed to verify the prediction mechanism. Additionally, different biological effects of *SH3D21* on
27 hepatocellular carcinoma cells were investigated by qRT-PCR, CCK-8 assay, colony forming assay and
28 Western blot analysis. Bioinformatics analysis and *in vitro* experiments revealed that the expression level
29 of *SH3D21* was up-regulated in hepatocellular carcinoma and correlated with the poor prognosis in
30 hepatocellular carcinoma patients. *SH3D21* effectively promoted the proliferation, invasion, and
31 migration as well as the formation of immunosuppressive microenvironment of hepatocellular carcinoma.
32 In addition, *SH3D21* can activate the PI3K/AKT/mTOR signaling pathway. *SH3D21* stimulates the
33 progression of hepatocellular carcinoma by activating the PI3K/AKT/mTOR signaling pathway, and
34 *SH3D21* can serve as a prognostic biomarker and therapeutic target for hepatocellular carcinoma.

35 **Keywords:** Hepatocellular carcinoma, SH3 domain containing 21 (*SH3D21*), Single-cell RNA
36 sequencing, PI3K/AKT/mTOR pathway

37 1. Introduction

38 Primary hepatoma is one of the most common malignant tumors, primarily hepatocellular carcinoma
39 (HCC). It is often characterized by a high degree of malignancy, with a propensity for metastasis and
40 recurrence following the treatment [1, 2]. Despite the availability of various treatment modalities,
41 including surgical resection, radiotherapy, and chemotherapy [2, 3], the prognosis for HCC patients
42 remains significantly poor [4]. Recent advancements in targeted therapy for HCC, such as application of
43 vascular endothelial growth factor receptor (VEGFR) inhibitors and programmed cell death 1 ligand
44 1(PD-L1) inhibitors, have sparked newfound hope [5, 6]. However, the efficacy of targeted therapy is
45 limited, thereby benefiting fewer than one-third of patients and only marginally prolonging the median

46 survival by a mere three months [7]. Hence, identification of effective biomarker is urgently needed for
47 targeted therapy of HCC.

48 The PI3K/Akt/mTOR pathway represents a crucial intracellular signaling cascade that can regulate
49 diverse cellular processes including proliferation, apoptosis, metabolism, and angiogenesis, by
50 functioning through intricate crosstalk with upstream or downstream molecules [8, 9]. Aberrant
51 activation of the PI3K/Akt/mTOR pathway has been reported in approximately 50% of hepatoma cases
52 [10], thereby exerting significant influence on the various facets of hepatoma initiation as well as
53 progression, including tumor cell proliferation, differentiation, metabolism, autophagy, and immune
54 regulation [11, 12]. Although multi-targeted tyrosine kinase inhibitors are being used as first-line
55 therapeutic agents targeting the PI3K/Akt/mTOR pathway, their efficacy in improving patient survival
56 remains modest. Notably, patients often develop acquired drug resistance during the treatment, thus
57 limiting the therapeutic options available [13]. This could be possibly attributed to the limited
58 understanding of the intricate interactions and metabolic roles of the PI3K/Akt/mTOR signaling axis in
59 hepatoma [14].

60 SH3 domain-containing 21 (*SH3D21*) is a SH3 domain containing protein that is localized within
61 the nucleus and plasma membrane. It functions by forming protein complexes and thereby modulating
62 intracellular signaling to regulate various key biological processes, including cell division, differentiation,
63 and growth and development [15]. Despite its biological significance, the current understanding of the
64 role of *SH3D21* in human tumors remains limited. Given the dearth of experimental studies related to
65 the role of *SH3D21* in tumorigenesis, this study was designed to elucidate its involvement in tumors and
66 evaluate its potential utility both as a novel biomarker and therapeutic target.

67 The association between *SH3D21* and prognosis as well as clinical features in HCC patients were

68 analyzed in this study. The mechanisms through which *SH3D21* can promote HCC and its effect on
69 PI3K/Akt/mTOR pathway activation were also investigated. The clinical samples and cell experiments
70 were employed to verify the experimental results.

71 **2. Materials and methods**

72 **Data source**

73 The transcriptome and clinical characteristics analysis data of *SH3D21* in HCC were obtained from
74 TCGA database (<https://portal.gdc.cancer.gov>) and ICGC database (<https://dcc.icgc.org/>)
75 (download time: 20221224). We have also incorporated the genetic variation information obtained from
76 the biological portal website (<https://www.cbioportal.org/>) [16]. Specifically, we have utilized a dataset
77 comprising 442 liver samples obtained from TCGA and Firhose Legacy. The data of human pan-cancer
78 was retrieved from the UCSC Xena online database (<https://xena.ucsc.edu/>) [17]. The downloaded data
79 included mRNA expressions and the clinical features of 33 different tumors.

80 **Differentially expressed genes (DEGs) and analysis of characterization of tumor** 81 **microenvironment**

82 The “Limma” software package in the R language was used to identify the various differentially
83 expressed genes (DEGs) and the expression levels of *SH3D21* in both the tumor tissues and control
84 tissues in the dataset. The differential gene screening was identified using the criteria of $\log_2FC > 1.0$ and
85 $FDR < 0.05$, thereby defining the genes exhibiting significant differential expression. We have stratified
86 the tumor-derived samples into up- and down-regulation groups based on the median *SH3D21* expression
87 level. The IOBR package in R language was employed to analyze the potential relationship between
88 *SH3D21* expression level and the characteristics of tumor microenvironment by ssGSEA algorithm.

89 **GO (Gene Ontology), GSEA (Gene-set Enrichment Analysis) and KEGG (Kyoto Encyclopedia of**

90 **Genes and Genomes) analyses of bulk samples**

91 The tumor samples in TCGA data set were divided into up- and down-regulation groups based on the
92 median expression level of *SH3D21* for the differential gene analysis. In addition, GO, KEGG and GSEA
93 enrichment analysis of the differential genes were performed. The tumor samples in ICGC data set were
94 also divided into up- and down-regulation groups according to the median expression level of *SH3D21*
95 for differential gene analysis. Thereafter, the correlation between the expression level of *SH3D21* and
96 the differential genes was analyzed (CoR=0.4, $P<0.05$). Subsequently, the high and low expression
97 differential genes were fed into WebGestalt (www.WebGestalt.org), an online bioinformatics website
98 that utilizes the KEGG database [18]. $P<0.05$ was considered to be a statistically different enrichment
99 pathway.

100 **Single-cell sequencing sample quality control and cell type identification**

101 The quality control process of the single-cell sequencing samples was conducted using Seurat (version
102 4.15) [19]. To ensure high-quality cells for the downstream analysis, the following criteria were applied:
103 The cells expressing fewer than 500 or more than 6000 total genes were filtered out, cells with over 15%
104 mitochondrial genes were excluded and the genes expressed in fewer than three cells were removed.
105 Overall, a total of 60,437 cells were detected and the analysis incorporated 19,125 different genes. The
106 batch effects were corrected using the Harmony R package, whereas the linear regression was employed
107 to eliminate effects of the cell cycle. To identify the principal clusters, the Seurat FindClusters function
108 (resolution = 0.5) was utilized and the top 30 principal component analysis (PCA) components were
109 selected for further analysis using the gravel plot. The resulting clusters were thereafter visualized using
110 “tSNE” and “UMAP” plots. The FindAllMarkers function of Seurat was employed to identify cell
111 markers for each cluster. To identify major cell types and provide annotations, the CellMarker database

112 (<http://xteam.xbio.top>) was combined with the data source of the cell surface markers [20].

113 **InferCNV**

114 The R software copyKAT package was used for CNV analysis of the hepatocytes present in the samples,
115 and the T cells were used as normal reference cells. The normal hepatocytes and HCC cells were
116 distinguished according to the changes of CNV.

117 **Differential gene identification and GSVA (Gene-set Variation Analysis) enrichment analysis in** 118 **the single-cell samples**

119 A nonparametric and unsupervised algorithm for gene set variation analysis (GSVA) was utilized to
120 evaluate the pathway activity in normal hepatocytes, *SH3D21*-positive HCC cells, and *SH3D21*-negative
121 HCC cells. The geneset used for GSVA enrichment analysis was Hallmark geneset.

122 **Pseudotime trajectory analysis**

123 The Monocle2 package (v2.8.0) of R software was employed to perform the pseudo-time series analysis
124 of HCC cells [21]. The input for the analysis consisted of the original count matrix obtained from the
125 data processed by Seurat. The new Cell Data Set function was utilized to create an expression family
126 object, facilitating the specification of the lower detection limit as 0.5. An unsupervised analysis method
127 was employed to explore the cell development trajectory using the highly variable genes selected by
128 Monocle. The dispersion empirical parameter was set to 1, whereas the remaining data analysis
129 parameters were selected as the default settings.

130 **Immunotherapy prediction and chemotherapy sensitivity analysis**

131 Three distinct immunotherapy cohort studies GSE78220, GSE67501 and IMvigor210 were collected
132 from GEO database to examine the potential correlation between *SH3D21* and immunotherapy. The
133 tumor immune atlas database (The Cancer Immunome Atlas, <https://tcia.at/>) was also used to observe

134 the treatment response of *SH3D21* to PD1 and CTLA4. In addition, based on Cancer Drug Sensitivity
135 Genomics (GDSC), a public pharmacology portal, the chemotherapeutic agents sensitive to *SH3D21*
136 were estimated and the top 10 drugs were shortlisted for further analysis.

137 **Test and verify**

138 *Cell lines and cell culture*

139 LX-2, Huh7, HepG2, SK-HEP-1 cell line was provided by CTCC, Ltd (Wuxi, China). The frozen HepG2
140 (in Dulbecco's modified Eagle medium (DMEM, high glucose)), Huh-7 (in DMEM, high glucose, and
141 SK-HEP-1 (MEM-EBSS) cells were thawed at 37 °C and then resuspended into the corresponding
142 complete culture media. When the cells grew to approximately 80%, cell passage was executed.
143 Additionally, the cells were grouped and cultured in an incubator (Thermo, USA) at 37 °C. The cells
144 were thereafter collected and then stored for subsequent experiments.

145 *Tissue source*

146 The HCC tissues and normal hepatic tissue were procured from the different individuals undergoing liver
147 cancer resection or liver biopsy at the Department of Hepatobiliary Surgery, Ruikang Hospital Affiliated
148 to Guangxi University of Traditional Chinese Medicine between December 2022 and October 2023. The
149 studies were approved by the Ethics Committees of Ruikang Hospital Affiliated to Guangxi University
150 of Traditional Chinese Medicine. The assigned ethical review approval number: KY2022-045.

151 *Real-time, quantitative reverse transcription-polymerase chain reaction (qRT-PCR)*

152 Total RNA was extracted by using Trizol reagent (Invitrogen, Grand Island, New York, USA). Both the
153 concentration and purity of RNA were measured using a Nanodrop spectrophotometer (ThermoFisher
154 Science, Waltham, Massachusetts, USA). RNA was reverse transcribed into cDNA using a reverse
155 transcription kit (Takara, Dalian, China) in accordance with the manufacturer's instructions. SYBR

156 Select Master Mix (ThermoFisher Science, Waltham, Massachusetts, USA) was used for qRT-PCR
157 analysis. A QuantStudio™ 6 Flex real-time quantitative PCR system was employed for the data
158 collection. The samples obtained amplified in accordance with the following protocol: 95°C 5 mins,
159 95°C 40 cycles 30s, 60°C 40s, 72°C 1 min. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
160 used as an endogenous control. Each sample was prepared in triplicate. The $2^{-\Delta\Delta CT}$ method was used to
161 calculate the relative expression. The sequences of the qRT-PCR primers used for *SH3D21* were: forward:
162 5'-AGCAAGGAGGGCAATGACTCT-3', reverse: 5'-ACGCAGTACTTGCCACTCT-3'; GAPDH:
163 forward: 5'-GCAGCGTGATCCCTGCAAAAT-3', reverse: 5'-GCCTGTAGTCAGCAACTCATCG-3'.

164 ***Cell transfection***

165 Huh7 and HepG2 cells were seeded in six-well culture plate for 24 h (1×10^5 cells/well). Thereafter, the
166 cells were divided into the HepG2 and Huh7 group, the HepG2/Huh7+siRNA NC group and the
167 HepG2/Huh7+si-*SH3D21*-1, 2, 3 group. HepG2/Huh7+si-*SH3D21*-1, which was validated by RT-PCR
168 to be the optimized knockdown target sequence, was selected for the subsequent experiments. The DNA
169 sequence of *SH3D21* gene was amplified by PCR, digested, and then cloned into the expression vector
170 (PCI-neo). The expression vector was then transfected into HepG2 cells to enable up-expression of the
171 *SH3D21* gene; the group was confirmed to be the OE-*SH3D21* if the up-expression was validated by RT-
172 PCR. Additionally, Lipofectamine 2000 transfection reagent (1.5 μ L/mL, ThermoFisher, USA) was used
173 to transfect 50 nM gene fragments or 1 μ g of plasmid to HepG2 and Huh7 cells. After 48-hour
174 transfection, the samples were collected and stored.

175 ***Colony formation***

176 The samples were divided into the control group, the si-control group and the si-*SH3D21* group. After
177 transfection, the cell suspension was prepared once the cell growth was in the logarithmic phase. The

178 cells were then seeded into the six-well plates (Corning, USA) and incubated at 37 °C, 5% CO₂ and
179 saturated humidity for two weeks. The culture was terminated if the clones visible to the naked eyes
180 appeared in the dish. Afterward, the cells were rinsed with PBS twice and fixed with 5 mL of pure
181 methanol (Beijing Dingguo Changsheng Biotechnology Co., Ltd., China) for 15 min. The methanol was
182 then removed, and Giemsa staining solution (Beyotime, China) was added and incubated for 30 min. The
183 staining solution was removed, and the sample was dried in air. The cells were counted manually from
184 obtained images. Alternatively, clones with more than 10 cells were counted using a light microscope
185 (Olympus, Japan). The colony formation rate was calculated by using the formula (number of
186 clones)/(number of inoculated cells) × 100%.

187 ***Determination of cell viability***

188 Cell Counting Kit-8 (CCK-8) cell proliferation and cytotoxicity assay kit (Sigma-Aldrich, Merck KGaA,
189 Germany) was used to measure the viability of transfected Huh7 and HepG2 cells. The cells were seeded
190 in the wells of a 96-well plate and thereafter incubated for 24h, 48h, 72h, respectively. CCK-8 solution
191 (15 μL) was added to each well at the designated time intervals and incubated at 37°C for 4h. The
192 absorbance at 492 nm was measured using a microplate reader (Thermo Scientific, Waltham,
193 Massachusetts, USA). Each experiment was repeated independently in triplicate.

194 ***Western blot analysis***

195 HCC cells and tissues were lysed in radioimmunoprecipitation assay (RIPA) buffer (KeyGEN, Nanjing,
196 China) containing protease suppressors for 30 min. The protein concentration was quantified using a
197 bicinchoninic acid (BCA) kit (KeyGEN, Nanjing, China) in accordance with the manufacturer's protocol.
198 The total protein was subjected to heating at 95°C for 5 min. Thereafter, identical quantities of protein
199 were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The

200 separated proteins were transferred to polyvinylidene fluoride (PVDF) membranes after which
201 electrometastasis was applied and then blocked with 5% skimmed milk at the room temperature for 60
202 min. The membranes were then stored overnight at 4°C with an appropriate primary antibody. The panel
203 of antibodies used was as follows: *SH3D21*(1:1000; Proteintech No. 25767-1-AP, Chicago, USA),
204 mTOR (1:1000; Proteintech No. 66888-1-Ig, Chicago, USA), p-AKT (1:1000; Proteintech No. 66444-1-
205 Ig, Chicago, USA), p-PI3K (1:1000; Proteintech No. 4228, Chicago, USA), PI3K (1:1000; Proteintech
206 No. 20584-1-AP, Chicago, USA), AKT (1:4000; Proteintech No. 60203-2-Ig, Chicago, USA), and
207 GAPDH (1:5000; Proteintech No. 60004-1-Ig, Chicago, USA). After washing 3 times in TBST buffer,
208 the membranes were incubated at the room temperature for 1h with rabbit horseradish peroxidase (HRP)-
209 conjugated secondary antibody (1:1000, Beyotime. No. A0208, Shanghai, China) then washed with the
210 blocking solution and visualized by enhanced chemiluminescence (ECL, Thermo Fisher Scientific,
211 Waltham, Massachusetts, USA). Finally, quantity One gel analysis software was used to detect the signal
212 intensity of each membrane. The intensity was measured relative to that of GAPDH.

213 ***Immunohistochemical staining***

214 Following the dewaxing and antigen retrieval steps, the tissue sections were subjected to additional
215 treatments. First, incubation with 3% H₂O₂ (Beyotime, China) for 10 min and 0.1% Triton X-100
216 (Beyotime, China) at the room temperature for 10 min was conducted. Subsequently, 50 µL of 5% BSA
217 (Wuxi Puhe, China) was applied to the tissues and incubated at 37 °C for 1 hour to block non-specific
218 binding sites. The primary antibody, specifically *SH3D21* (dilution: 1:1000; Proteintech No. 25767-1-
219 AP, Chicago, USA), was proportionally diluted and then applied to the tissues, followed by incubation
220 at 37 °C for 2 h. After washing with PBS, a secondary antibody was added: Rabbit secondary antibody
221 (dilution: 1:200, Zhongshan Jinqiao, China) or Murine dimab (dilution: 1:200, Zhongshanjinqiao, China),

222 depending on the species sources of the primary antibodies used. Thereafter, incubation with the
223 secondary antibody was performed at 37°C for 1h. For visualization, diaminobenzidine (DAB) (Nakasugi
224 Kinbashi, China) color development was employed. Hematoxylin restaining was then conducted,
225 followed by sealing with the neutral gum. Finally, the prepared tissue sections were observed and
226 photographed under a microscope (Olympus, Japan) to evaluate the target staining and overall tissue
227 morphology.

228 *Invasion and Migration Experiments*

229 Matrigel matrix glue (BD Biosciences, USA) was diluted in a serum-free medium at 1:6, and 50ul was
230 evenly spread into the upper chamber of Transwell chamber (Corning, USA). The chamber was placed
231 in a 24-wellplateandincubated at 37°C for 4h to allow it to gelatinize. The cell density was adjusted to
232 2×10^5 cells/mL, and 100 μ L per well was inoculated into the upper chamber of transwell chamber. The
233 cells in the upper chamber were removed after 24h, fixed with methanol and 0.1% crystal violet (Beijing
234 Dingguo Changsheng Biotechnology, CHN) for 20min, stained for 10min, and washed twice with PBS.
235 The cells were then counted under an inverted optical microscope (Olympus, JPN).

236 *Scratch Wound-Healing Assay*

237 Huh7 and HepG2 cells were seeded in 6-well culture plates (Corning, USA) at 95–100% confluence.
238 The cells were harvested 48h after transfection. The scratch was created using a 200 μ L pipette tip. PBS
239 was used to wash the plates thrice to remove the cellular debris. The images for the wound closure were
240 captured at the different times (12, 24, 36 and 48 h) by microscope (Olympus, JPN).

241 **Statistical analysis**

242 The biological information analysis in this study was conducted by using R programming (version 4.15,
243 <https://www.r-project.org/>). Statistical analysis was performed by SPSS 27 and GraphPad Prism V7.0


244 software. The data has been presented as mean \pm standard deviation (SD). For comparison of means
245 between the two groups, T-test was applied. Analysis of variance (ANOVA) was employed to compare
246 multiple sets of values. The relationship between the expression of *SH3D21* and clinical features was
247 assessed using the Chi-square test. Survival analysis was performed using the Kaplan-Meier method, and
248 the log-rank test was used for the group comparisons. $P < 0.05$ was considered statistically significant.

249 **3. Results**

250 ***SH3D21* was highly expressed in HCC and related to poor outcomes of HCC patients**

251 The differential analysis of HCC transcriptome data from TCGA database (<https://portal.gdc.cancer.gov>)
252 revealed that the mRNA expression of *SH3D21* in HCC tissues was significantly higher than that in
253 normal hepatic tissue (logFC=1.937) (**Fig 1A**). Moreover, determination of the relationship between
254 *SH3D21* expression and clinical characteristics of HCC patients revealed that *SH3D21* was highly
255 expressed in females ($P=0.0099$) and increased with the elevation of tumor T-stage (**Fig 1B**), histological
256 grading (**Fig 1C**) and clinical stage (**Fig 1D**). High expression of *SH3D21* resulted in shorter survival of
257 HCC patients (**Fig 1E**). However, no correlation was observed between Progression Free Survival (PFS),
258 Disease Free Interval (DFI), and Disease-Specific Survival (DSS) ($P > 0.05$). Univariate and multivariate
259 analyses were conducted to investigate the various clinical features and the possible relationship between
260 *SH3D21* expression and the survival status of patients. High expression of *SH3D21* remained a
261 significant independent predictor for patients with HCC (**Fig 1I, J**). In addition, HCC dataset (LIRI-JP)
262 was downloaded for validation from the ICGC (<https://dcc.icgc.org/>) database. The results revealed that
263 *SH3D21* was highly expressed in HCC (logFC= 1.442) (**Fig 1F**) and increased with both the elevated
264 histological grading (**Fig 1G**) and clinical stage of tumor tissues (**Fig 1H**). The above results illustrated
265 that *SH3D21* was highly expressed in HCC and was associated with poor clinical outcomes in HCC

266 patients. To experimentally validate the predicted results, three HCC-derived samples and normal liver
267 tissue-derived samples were collected. Immunohistochemical staining and Western blot analysis to
268 determine the expression of *SH3D21* protein in HCC and normal liver tissues was performed. The results
269 demonstrated that the level of *SH3D21* protein was significantly higher in the tumor samples compared
270 to the normal liver tissues (**Fig 1K-M**) (**Full length gel Supplementary Fig 1**). These results confirmed
271 the prediction that the expression of *SH3D21* was increased in HCC.



272

273 **Fig: 1** *SH3D21* was highly expressed and associated with poor clinical outcomes in HCC patients. **A** Differential

274 analysis of mRNA expression of *SH3D21* in normal control and HCC tissues obtained from TCGA database source

275 samples. **B-D** Relationship between the expression level of *SH3D21* and T Stage (B), Grade (C), and stage (D) of

276 HCC patients in TCGA database. **E** Impact of high expression of *SH3D21* on prognosis of HCC patients. **F**
277 Differential analysis of mRNA expression of *SH3D21* in the normal control and HCC tissues from ICGC database
278 source samples. **G, H** Correlation between *SH3D21* expression level and Grade (G) and Stage (H) in ICGC database
279 source samples. **I, J** Univariate and multifactorial analysis of the clinical characteristics of HCC patients and
280 correlation between *SH3D21* gene expression and survival status of patients from TCGA database. **K, M** The
281 expression of *SH3D21* protein in HCC and normal liver tissue samples was detected by immunohistochemical
282 staining and Western blotting.

283 **Determination of Mutation as well as methylation status of *SH3D21* in HCC and relationship**
284 **between *SH3D21* expression and TME**


285 To investigate the impact of *SH3D21* genetic variation on mRNA expression, the mutation of *SH3D21*
286 in HCC samples was next analyzed using the online database ccBioPortal (<https://www.cbioportal.org/>).
287 As demonstrated, our analysis revealed that *SH3D21* was genetically altered in 6.88% (24/349) of the
288 samples. Among these alterations, the highest frequency was observed in cases of high mRNA expression
289 (20/349, 5.73%), followed by mutations (2/349, 0.57%), amplification, and deep deletion (1/349, 0.29%)
290 (**Fig 2A**). The most common mutation in the *SH3D21* gene was the I428T missense mutation (0.07%),
291 which was diploid in nature. The second most frequent mutation was the M355Cfs*38 frameshift
292 mutation (0.06%), resulting in a mild copy number loss (**Fig 2B**). Further correlation analysis between
293 the mutation type and mRNA expression of *SH3D21* revealed that the increase in mRNA expression
294 could be primarily attributed to gene expansion and significant amplification events (**Fig 2C**). Therefore,
295 mRNA expression of *SH3D21* was negatively related to the methylation level (**Fig 2D**). Overall, these
296 findings indicated that *SH3D21* mRNA expression levels were associated with gene amplification.
297 To explore the possible function of *SH3D21* in promoting the clinical progression of HCC, TCGA and

298 ICGC datasets were employed to analyze the correlation between the expression of *SH3D21* and the
299 microenvironment characteristics of HCC. The results revealed that increase of *SH3D21* expression was
300 associated with EMT2, EMT3, cell cycle, DNA replication, TH1/TH2 cell regulation, MDSC and TIP
301 tumor immune cell infiltration. Therefore, we speculated that there was a significant correlation between
302 the above characteristics and the expression level of *SH3D21*. In addition, the above characteristics
303 displayed a consistent trend in TCGA (**Fig 2E, F**) and ICGC data sets (**Fig 2G, H**), thereby indicating
304 that *SH3D21* can play a vital role in regulating the proliferation, invasion, migration, and formation of
305 immunosuppressive microenvironment of HCC.
306

313 and TME characteristics in TCGA dataset. **G** Relationship between *SH3D21* gene expression and
314 TME characteristics in the ICGC dataset. **H** Correlation analysis between *SH3D21* gene
315 expression and TME characteristics in ICGC dataset.

316 ***SH3D21* can promote the proliferation, invasion, and migration of HCC cells as confirmed by *in***
317 ***vitro* experiments**

318 Three distinct kinds of HCC cells, SK-HEP-1, Huh-7 and HepG2 were selected to observe the mRNA
319 and protein expression of *SH3D21*. The results revealed that the mRNA and protein expression levels of
320 *SH3D21* were markedly higher in the three HCC cells in comparison to the control LX-2 cells (**Fig 3A,**
321 **B**) (**Full length gel Supplementary Fig 2**). Interestingly, silencing of *SH3D21* in HepG2 and Huh-7
322 cells resulted in reduced cell viability at 48h and 72h ($P<0.01$) (**Fig 3C, F**) and a significant decrease in
323 the cell colony forming ability ($P<0.01$) (**Fig 3D, E**). Moreover, silencing the expression of *SH3D21*
324 significantly inhibited the wound healing ability (**Fig 3G, I**), as well as reduced the invasive ability (**Fig**
325 **3H, K**) and the number of migrating HCC cells (**Fig 3H, J**). The above results confirmed that
326 high expression of *SH3D21* can promote the proliferation, migration, and invasion of
327 HCC cells.



328

329 **Fig. 3** *SH3D21* was highly expressed and promoted proliferation, invasion, and migration of HCC cells.

330 **A, B** *SH3D21* exhibited higher mRNA and protein expression levels in HCC cell lines than in human

331 hepatic stellate cells. **C, F** Silencing of *SH3D21* gene significantly reduced the survival of HepG2 and

332 Huh-7 cells at 48h and 72h, respectively. **D, E** Silencing *SH3D21* markedly inhibited colony-forming
333 ability of HCC cells. **G, I** Silencing *SH3D21* significantly suppressed wound healing ability of HCC cells.
334 **H, K** Silencing *SH3D2* significantly reduced the invasive ability of HCC cells. **H, J** Silencing *SH3D2*
335 significantly attenuated the number of migrating HCC cells.

336 **Bulk sample analysis of TCGA and ICGC databases revealed that *SH3D21* can cause**
337 **activation of PI3K/AKT signaling pathway in HCC**

338 HCC samples in the TCGA dataset were divided into high- and low- expression groups
339 according to the median value of *SH3D21* expression for the differential analysis, as
340 well as GO (**Fig 4A**) and KEGG enrichment analysis (**Fig 4B**) were performed for the
341 differential genes. Biological process (BP) results of GO enrichment analysis revealed
342 that *SH3D21* was mainly involved in organic acid metabolic process, carboxylic acid
343 metabolic process and ion transport. Cellular component (CC) results demonstrated that
344 *SH3D21* was located on the cell surface, intrinsic component of plasma membrane and
345 integral component of plasma membrane. Molecular function (MF) of *SH3D21* included
346 transmembrane transporter activity, oxidoreductase activity and transporter activity.
347 KEGG enrichment analysis revealed that the differential genes were mainly enriched in
348 regulation of retinol metabolism, metabolism of xenobiotics by cytochrome P450 and
349 metabolic pathways. In addition, HCC samples in the TCGA dataset were divided into
350 high- and low- expression groups according to the median value of *SH3D21* expression
351 for GSEA pathway enrichment analysis. GSEA enrichment analysis further indicated that
352 the differential genes associated with *SH3D21* high-expression group were enriched in
353 cell cycle, DNA replication, mismatch repair, tight linking and PI3K-AKT-mTOR

354 pathway. All these pathways are primarily related to HCC cell proliferation and invasion.

355 The differential genes associated with *SH3D21* low-expression group were found to be

356 enriched in drug metabolism cytochrome P450, fatty acid metabolism, complement and

357 coagulation cascades and PPAR signaling pathway (**Fig 4C**).

358 KEGG enrichment analysis of *SH3D21*-associated differential genes was performed

359 using the ICGC dataset to validate GSEA results from the TCGA dataset. The results

360 suggested that the differential genes associated with *SH3D21* high-expression group

361 were mainly enriched in pathways related to the tumor proliferation and invasion, such

362 as cell cycle, PI3K-AKT signaling pathway, DNA replication, mismatch repair, gap

363 linking, and VEGF angiogenesis pathway. The differential genes associated with

364 *SH3D21* low-expression group were enriched in complement and coagulation cascades,

365 drug metabolism, arachidonic acid metabolism and PPAR signaling pathway (**Fig 4D**).

366 The above results were similar to the GSEA enrichment analysis results of TCGA dataset.

367 Among the pathways enriched by the differential genes in *SH3D21* high- expression

368 group, PI3K-AKT signaling pathway was identified. The PI3K-AKT signaling pathway


369 can promote multiple signaling processes and regulate a variety of cellular functions,

370 such as metabolism, proliferation, cell survival, growth, and angiogenesis. Activation of

371 PI3K pathway can not only promote cell cycle progression, migration, but also inhibit

372 cellular inflammation and apoptosis. Therefore, the above results indicated that the high

373 expression of *SH3D21* has a potential role in activating PI3K signaling cascade.



374

375 **Fig. 4** *SH3D21* promoted substantial activation of PI3K/AKT signaling pathway in HCC. **A, B** GO and

376 KEGG enrichment analysis of differential genes associated with *SH3D21* high and low

377 expression groups in TCGA dataset. **C** GSEA enrichment analysis of differential genes associated with

378 *SH3D21* high and low expression groups in TCGA dataset. **D** KEGG enrichment analysis of differential


379 genes associated with *SH3D21* high and low expression groups in ICGC dataset.

380 **Single-cell sequencing analysis and *in vitro* experiments revealed that *SH3D21* can activate**
381 **PI3K/AKT signaling pathway in HCC cells**

382 Following data acquisition from Lu *et al.* [22], which involved single-cell sequencing of hepatoma from
383 the GEO database, we focused on analyzing the single-cell sequencing results obtained from 10 different
384 HCC tissues and 8 para-cancerous control tissues in the dataset. After the batch correction was performed
385 using the harmony algorithm to eliminate its potential effect on the cell clustering (**Fig 5B**). This resulted
386 in the formation of distinct 18 cell groups (**Fig 5A**). We utilized marker genes provided in the source
387 literature to perform the cell type annotation (**Fig 5C**). Subsequently, HCC cells, macrophages,
388 monocytes, B cells, T cells and NK cells were selected for further analysis (**Fig 5D**). Notably, our cell
389 type annotation revealed that *SH3D21* was expressed in all the above 6 cell type (**Fig 5E**).

390 The hepatocyte subsets were further analyzed, and cellular CNV analysis was performed on hepatocytes
391 using Copykat (**Fig 5F**). After the diploid and heteroploidy of hepatocytes were identified, normal
392 hepatocytes and HCC cells were distinguished (**Figs 5F-H**). The differential analysis between the
393 hepatocytes and HCC cells revealed that *SH3D21* was highly expressed in HCC cells (**Fig 5I**). The
394 hepatocyte subsets were further divided into *SH3D21* positive HCC cells, *SH3D21* negative HCC cells
395 and normal hepatocytes, and GSVA enrichment analysis was conducted on the above three groups. The
396 results of GSVA enrichment analysis revealed that *SH3D21* positive HCC cells exhibited enrichment in
397 the different pathways associated with tumor proliferation, invasion, and immunosuppression, such as
398 PI3K/AKT/mTOR, angiogenesis, EMT, IL6-JAK-STAT3. Interestingly, *SH3D21* negative HCC cells
399 exhibited enrichment in various pathways associated with hedgehog signaling, apical junction,
400 coagulation, and hypoxia. GSVA enrichment analysis revealed that normal hepatocytes exhibited

401 enrichment in various pathways associated with inflammation and immune response, such as TNFA
402 signaling via NFkB, inflammatory response, complement, P53, apoptosis (**Fig 5J**). These results
403 indicated that *SH3D21* was highly expressed in HCC cells and can potentially activate the
404 PI3K/AKT/mTOR pathway, thus promoting the growth of HCC.
405 Furthermore, *in vitro* experiments to examine above results. we observed that overexpression of *SH3D21*
406 led to increased protein levels of mTOR, p-PI3K/PI3K, and p-AKT/AKT in HepG2 and Huh-7 cells
407 (**Figs 6A, B**) (**Full length gel Supplementary Fig 3**). Conversely, when *SH3D21* was knocked down,
408 reverse effects on the aforementioned proteins in HepG2 and Huh-7 cells were observed (**Figs 6C, D**)
409 (**Full length gel Supplementary Fig 4**). These findings indicated that *SH3D21* could activate
410 PI3K/AKT/ mTOR signaling pathway in HCC cells.



411

412 **Fig. 5** Single-cell sequencing revealed that *SH3D21* caused activation of PI3K/AKT signaling pathway


413 in HCC. **A** For clustering of cells after the batch correction. **B** For clustering of cells after the batch

414 correction was performed using the harmony algorithm. **C** Expression of the various cell marker genes

415 in clustering cells. **D**, **E** Cell types that were included in subsequent analyses and expression of *SH3D21*

416 in various cell types. **F-H** For clustering of subsets of hepatocytes(**F**), Copykat was used to perform the

417 cellular CNV analysis on hepatocytes(G). Distribution of the normal hepatocytes and HCC cells (H). I
 418 Difference analysis of *SH3D21* expression between hepatocytes and HCC cells. J GSVA enrichment
 419 analysis of *SH3D21*-positive, *SH3D21*-negative HCC cells and the control hepatocytes.



420
 421 **Fig. 6** *In vitro* experiments revealed that *SH3D21* can activate the PI3K/AKT signaling pathway. **A, B**
 422 Protein expression electrophoretograms of key proteins in PI3K/AKT signaling pathway after *SH3D21*
 423 silencing and overexpression in HepG2 and Huh-7 cells, respectively. **C, D** Ratio of the gray value of
 424 key proteins in PI3K/AKT signaling pathway after *SH3D21* silencing and overexpression in HepG2 and
 425 Huh-7 cells.

426 Immune landscape of *SH3D21* in HCC and its response to immunotherapy


427 The correlation analysis between *SH3D21* expression and TME based on TCGA database revealed that
 428 high expression group of *SH3D21* possessed higher immune score than low expression group of *SH3D21*
 429 ($P < 0.001$) (**Fig 7A**). This result is also confirmed in ICGC database analysis (**Fig 7B**). However, the
 430 analysis results of TCGA and ICGC databases revealed that there was no statistically significant
 431 correlation observed between the expression level of *SH3D21* and immune scores ($P > 0.05$). In addition,

432 TCGA and ICGC datasets also revealed that there was no statistical difference observed in tumor matrix
433 score and tumor purity score between high- and low- expression groups of *SH3D21*. The CIBERSORT
434 method was employed to analyze the possible relationship between expression of *SH3D21* and immune
435 cell infiltration in TCGA data set. The results revealed that high expression of *SH3D21* accompanied by
436 M0 immune cell infiltration ($P<0.001$) (**Fig 7C**). Moreover, the high expression of *SH3D21* was
437 positively correlated with M0 cell infiltration ($R=0.5$, $P=7.1E-08$) (**Fig 7D**). This result was also
438 confirmed in ICGC database analysis (**Fig 7E**). Based on analysis results of the immune
439 microenvironment characteristics before, it was suggested that *SH3D21* could regulate immunity through
440 affecting macrophages, MDSC and Th2 cells.

441 The correlation analysis between *SH3D21* and immune checkpoints in TCGA (**Fig 7G**) and ICGC (**Fig**
442 **7F**) datasets demonstrated that high expression of *SH3D21* was positively correlated with the expression
443 of immune checkpoint molecule. This observation indicated that high expression of *SH3D21* can affect
444 immunosuppression microenvironment of HCC. In addition, the correlation between *SH3D21* and the
445 expression level of tumor-related factors MKI67 , TP53 , KRAS, CTNNB1 and IDH1 were also
446 investigated. The analysis based on TCGA (**Fig 7H**) and ICGC (**Fig 7I**) datasets revealed that the
447 expression of *SH3D21* was positively correlated with MIK67, TP53, KRAS as well as CTNNB1, and
448 the expression of *SH3D21* was negatively correlated with IDH1. In addition, the correlation analysis
449 between *SH3D21* and the stemness of HCC cells revealed that *SH3D21* was negatively correlated with
450 DNAsI of HCC cells (**Fig 7H**), but there was no significant correlation between *SH3D21* and RNAsi.

451 Immunotherapy data in GEO database was further analyzed to observe the intervention effect of
452 immunotherapy on *SH3D21*. These data included Melanoma Treatment study GSE78220, Renal Cancer
453 Treatment Study GSE67501, Urothelial Cancer Treatment Study IMvigor, and immunotherapy data from


454 TCIA database (<https://tcia.at/patients>). It was found that none of the above immunotherapies had a
455 statistically significant effect on *SH3D21* ($P > 0.05$), thus indicating that *SH3D21* was not sensitive to
456 immunotherapy. Thereafter, cancer-related drug sensitivity genomics (GDSC, Genomics of Drug
457 Sensitivity in Cancer) were used to screen *SH3D21* sensitive drugs. The top 10 sensitive drugs identified
458 were AMG-706, ATRA, CEP-701, GSK1904529A, JNK-9L, JQ12, LFM-A13, PFI-1, SB505124 and
459 YK4-279.



460

461 **Fi. 7** Immune landscape of *SH3D21* in HCC. **A, B** The correlation between expression of *SH3D21* and

462 TME based on TCGA and ICGC data sets. **C** The correlation between high- and low- expression of
 463 *SH3D21* and immune cell infiltration. **D, E** The correlation analysis of expression of *SH3D21* and M0
 464 cell infiltration based on TCGA and ICGC data sets. **F, G** The correlation analysis of high-expression of
 465 *SH3D21* and expression of immune checkpoint molecular based on ICGC and TCGA datasets. **H** The
 466 correlation analysis between *SH3D21* and MIK67, TP53, KRAS, CTNNB1 and IDH1, and correlation
 467 analysis between *SH3D21* and DNAsI and RNAsI based on the TCGA dataset. **I** The correlation analysis
 468 between *SH3D21* and MIK67, TP53, KRAS, CTNNB1 and IDH1 based on ICGC dataset.




469
 470 **Fig. 8** Top 10 sensitive drugs to *SH3D21* in drug sensitivity experiments.

471 **Alterations in *SH3D21* during HCC cell development, construction of predictive models and**
 472 ***SH3D21* expression in pan-cancer**

473 A mimetic time-series analysis was performed to observe the potential changes in *SH3D21* during the
 474 development of HCC cells. The results revealed that *SH3D21* was at a relatively stable level during the
 475 development of HCC cells and did not show any significant decrease or increase with the progression of
 476 HCC (**Fig 9A, B**).

477 To aid clinicians assess patients' prognoses based on the aforementioned parameters, we established a
478 nomograph of different prognostic factors including *SH3D21* expression, patient age, gender,
479 hepatocellular carcinoma stage, grade, and several other variables to predict the OS of the patients (**Fig**
480 **9C**). The multivariate ROC curve analysis demonstrated that *SH3D21* expression possessed predictive
481 value for one-year (AUC=0.764), three-year (AUC=0.750) and five-year (AUC=0.752) survival rates in
482 HCC patients (**Fig 9D**), the fitting curve revealed that the model had good reliability.

483 Finally, the mRNA expression and clinical data of *SH3D21* in 33 tumors were downloaded from the
484 UCSC Xena online database (<https://xena.ucsc.edu/>) to observe the differential expression of *SH3D21* in
485 different tumors and the effect on patient prognosis. We set the number of normal sample cases in the
486 tumors to be greater than or equal to 1. A total of 24 tumors were included in the analysis. Interestingly,
487 the differential expression of *SH3D21* was observed in 19 tumors in comparison to the normal tissues.
488 The expression of *SH3D21* was elevated in 17 tumors ($P<0.05$), decreased in 2 tumors ($P<0.05$), and did
489 not differ in the remaining 5 tumors ($P>0.05$) (**Fig 9F**). We divided *SH3D21* into two groups, high and
490 low, according to the median value of *SH3D21* expression in 19 tumors, and observed the effect of
491 different expression on patients' prognosis. High *SH3D21* expression could lead to poor prognosis in
492 patients with HCC in addition to kidney renal clear cell carcinoma (KIRC) (**Fig 9G**), whereas high
493 *SH3D21* expression could prolong patients' survival in head and neck squamous cell carcinoma (HNSC)
494 (**Fig 9I**) and breast invasive carcinoma (BRCA) (**Fig 9H**). The results of a further univariate analysis
495 indicated that *SH3D21* could be used as an influential factor affecting patient prognosis in LIHC, KIRC,
496 BRCA and HNSC tumor types (**Fig 9E**). This result suggested that the function of *SH3D21* in various
497 tumors varies depending on the tumor type.



498

499 **Fig. 9** Alterations of *SH3D21* during HCC development, construction of predictive models and *SH3D21*

500 expression in pan-cancer. **A**, **B** Proposed temporal analysis of *SH3D21* in development of HCC. **C**

501 Nomograph of prognostic factors predicting OS of patients based on multiple variables (including:

502 *SH3D21* expression, patient age, gender, hepatocellular carcinoma stage, grade). **D** ROC curve

503 construction of expression level of *SH3D21* and its predictive value for survival of HCC. **E** Univariate

504 analysis of *SH3D21* on the prognosis of 33 tumor patients. **F** Differential analysis of *SH3D21* expression

505 in 24 tumors. **G-I** Effect of high *SH3D21* expression on the prognosis of patients with KIRC (G), BRCA
506 (H) and HNSC (I).

507 **4. Discussion**

508 In this study, the role of *SH3D21* in HCC was investigated in detail. The results revealed that expression
509 level of *SH3D21* was increased in HCC and associated with poor prognosis of HCC patients. *SH3D21*
510 was found to promote the proliferation, invasion, and migration of HCC cells, and can activate
511 PI3K/AKT/ mTOR signaling pathway.

512 *SH3D21* gene is located at 1p34.3 locus and encodes a protein with a molecular weight of 71 kDa. In
513 terms of subcellular localization, *SH3D21* is found in both the nucleus and the cytoplasmic membrane.

514 Functionally, *SH3D21* can function as a signaling molecule within the cells by forming complexes with
515 other proteins. For instance, in a previous study by Jacklyn N. Hellwege et al., it was discovered that two
516 single nucleotide polymorphisms within the *SH3D21* gene were associated with Resting Metabolic Rates
517 (RMR) based on exome array analysis [15]. Moreover, in another study, Mohammad Masoudi et al.

518 utilized the Pickles database and identified the requirement of *SH3D21* gene for maintaining the survival
519 of NCIH526 lung cancer cell line. Furthermore, in the context of pancreatic cancer research, *SH3D21*

520 has been identified as a novel sensitizer to gemcitabine treatment [23]. Despite these findings, our
521 understanding of the exact role played by *SH3D21* in tumorigenesis remains relatively limited. Hence,

522 further research is warranted to comprehensively elucidate the potential involvement of *SH3D21* in HCC.

523 In the analysis of HCC samples from the TCGA database, *SH3D21* was found to be highly expressed in
524 HCC, and the increased expression of *SH3D21* was positively correlated with the histological grade,

525 clinical stage, and T stage of HCC, thereby suggesting that *SH3D21* has a key role in promoting the
526 clinical progression of HCC. This conclusion was also confirmed by the analysis of the HCC dataset

527 from the ICGC database. The IOBR package was further employed to analyze the correlation between
528 *SH3D21* and TME characteristics. TCGA and ICGC database analysis consistently revealed that high-
529 expression of *SH3D21* was associated with EMT, cell cycle, DNA replication, TH1, TH2 cell regulation,
530 MDSC and TIP immune cell infiltration. These results indicated that *SH3D21* can effectively promote
531 the clinical progression of HCC by stimulating the proliferation and invasion of HCC cells and generating
532 tumor immunosuppressive microenvironment. To further investigate the cell types that *SH3D21*
533 specifically acts on, HCC single-cell sequencing dataset from the GEO database was employed and by
534 analyzing the expression of *SH3D21* in different types of cells, the primary cellular role of *SH3D21* was
535 determined. The results revealed that *SH3D21* was expressed on HCC cells, macrophages, monocytes,
536 B cells, T cells and NK cells. This indicated that *SH3D21* had important functional effects on all the
537 above cells. In this study, only HCC cells were selected for follow-up research.

538 A single-cell dataset from the GEO database revealed that *SH3D21* was expressed at higher levels in
539 HCC samples in comparison to the normal hepatocytes. The role of *SH3D21* in promoting the
540 proliferation and invasion of HCC cells was further verified by CCK8, cloning, invasion, and migration
541 experiments. In order to further explore the specific mechanism of *SH3D21* promoting the progression
542 of HCC cells, GSEA analysis results of TCGA database, KEGG analysis results of ICGC database and
543 GSVA analysis results of single cell sequencing dataset were used. The results of enrichment analysis
544 revealed that cell cycle, PI3K-Akt, DNA replication, mismatch repair, gap link, and VEGF angiogenesis
545 pathways were significantly enriched in all the above three datasets. However, the potential effect of
546 *SH3D21* on activation of PI3K-Akt signaling pathway was the primary focus of this study. The PI3K-
547 Akt signaling pathway has been implicated in the regulation of cell proliferation, invasion, apoptosis
548 signaling processes. Activation of PI3K pathway can not only promote the cell cycle progression and

549 tumor cell migration, but also inhibit immune cells, thereby constructing a tumor immunosuppressive
550 microenvironment.

551 Activation of the PI3K/AKT/mTOR signaling pathway can occur through diverse mechanisms, including
552 AKT-induced phosphorylation of apoptosis and cell cycle blocking factors such as BAD (BCL2-related
553 cell death agonist), MDM2 (ubiquitin ligase of p53), FOXO (apoptosis-inducing transcription factor),
554 IKK (inhibitor of kappa B kinase), and I κ B (I κ B kinase, which acts as a inhibitor of the transcription
555 factor NF- κ B). Interestingly, targeted inhibition of these factors can lead to enhanced activity of cell
556 cycle, DNA replication, and other associated signaling pathways [24, 25]. In addition, due to metabolic
557 reprogramming in tumors, abnormal activation of PI3K/AKT/mTOR pathway can promote the
558 immunosuppressive response [26], which in turn can lead to the formation of the immunosuppressive
559 network of tumors [27]. PI3K/AKT/ mTOR signaling pathway also plays a role in regulating M1/M2
560 polarization of macrophages [28], similar to the tumor-associated macrophage (TAM) switch between
561 immune stimulation and immune suppression [29]. In addition, PI3K/AKT/mTOR signaling pathway
562 also plays a significant role in promoting glycolytic metabolism in HCC cells, which can cause the
563 abnormal accumulation of lactic acid. As a product of glycolysis, lactic acid produced by the tumor cells
564 can promote M2-like polarization of tumor-associated macrophages [30-32]. Moreover, M2-like
565 polarization of tumor-associated macrophages can inhibit anti-tumor immunity, stimulate tumor
566 angiogenesis, enhance tumor cell invasion as well as infiltration, and further promote the tumor growth
567 [33-35], thus forming a vicious cycle. In this study, the activation of PI3K/AKT/ mTOR signaling
568 pathway by high expression of *SH3D21* was confirmed by further experiments.

569 Considering that there are few studies reported on potential role of *SH3D21* in tumorigenesis, the
570 expression of *SH3D21* in pan-cancer and its influence on pan-cancer were also analyzed. Among the 33

571 different tumor types investigated, *SH3D21* exhibited altered expression in 19 tumor tissues in
572 comparison to the normal tissues. Specifically, *SH3D21* expression was increased in 17 tumors ($P<0.05$)
573 and decreased in 2 tumors ($P<0.05$). Interestingly, although *SH3D21* expression was elevated in certain
574 tumors such as BLCA, ESCA, and READ, it did not significantly impact the overall patient survival
575 ($P>0.05$). These observations indicate that the influence of *SH3D21* might significantly vary across
576 different tumor types.

577 **5. Conclusion**

578 In summary, *SH3D21* can display elevated expression levels in various tumor types, including primary
579 HCC. Notably, *SH3D21* can promote the proliferation and invasion of HCC by activating
580 PI3K/AKT/mTOR signaling pathway. Consequently, *SH3D21* could serve as a promising candidate for
581 targeted intervention in hepatoma treatment.

582 **Supporting information**

583 **S1 Raw images** (PDF)

584 **S2 Raw images** (PDF)

585 **Author contributions**

586 **Conceptualization:** Ning Luo

587 **Data curation:** Wangxia Tong, Tao Lu

588 **Formal analysis:** Li Liu, Jibing Chen

589 **Methodology:** Rong Liu, Li Liu, Wangxia Tong, Tao Lu

590 **Resources:** Wangxia Tong, Ning Luo and Jibing Chen

591 **Supervision:** Jibing Chen

592 **Validation:** Jibing Chen

593 **Writing-original draft:** Wangxia Tong

594 **Writing-review & editing:** Wangxia Tong, Ning Luo

595 **Acknowledgments**

596 Not applicable

597 **Consent for publication**

598 This article has been authorized by all authors and agreed to be published.

599 **Ethical approval**

600 The studies involving human participants were reviewed and approved by the Ethics Committees of
601 Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine. The assigned ethical review
602 approval number: KY2022-045. The patients/participants provided their written informed consent to
603 participate in this study.

604

605 **References**

- 606 1. Villanueva A. Hepatocellular Carcinoma. *New Engl J Med.* 2019;380(15):1450-62.
607 <http://doi.org/10.1056/NEJMra1713263> PMID:30970190
- 608 2. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. *Lancet.* 2018;391(10127):1301-14.
609 [http://doi.org/10.1016/S0140-6736\(18\)30010-2](http://doi.org/10.1016/S0140-6736(18)30010-2) PMID:29307467
- 610 3. Wong KM, King GG, Harris WP. The Treatment Landscape of Advanced Hepatocellular
611 Carcinoma. *Curr Oncol Rep.* 2022;24(7):917-27. <http://doi.org/10.1007/s11912-022-01247-7>
612 [PMID:35347594](https://pubmed.ncbi.nlm.nih.gov/35347594/) PMID:35347594
- 613 4. Hartke J, Johnson M, Ghabril M. The diagnosis and treatment of hepatocellular carcinoma. *Semin*
614 *Diagn Pathol.* 2017;34(2):153-9. <http://doi.org/10.1053/j.semmp.2016.12.011> PMID:28108047
- 615 5. Kelley RK, Rimassa L, Cheng AL, Kaseb A, Qin S, Zhu AX, et al. Cabozantinib plus atezolizumab
616 versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label,
617 randomised, phase 3 trial. *Lancet Oncol.* 2022;23(8):995-1008. [http://doi.org/10.1016/S1470-](http://doi.org/10.1016/S1470-2045(22)00326-6)
618 [2045\(22\)00326-6](https://pubmed.ncbi.nlm.nih.gov/35798016/) PMID:35798016

- 619 6. Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, et al. Nivolumab versus sorafenib in
620 advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label,
621 phase 3 trial. *Lancet Oncol.* 2022;23(1):77-90. [http://doi.org/10.1016/S1470-2045\(21\)00604-5](http://doi.org/10.1016/S1470-2045(21)00604-5)
622 PMID:34914889
- 623 7. McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. *Hepatology.*
624 2021;73 Suppl 1(Suppl 1):4-13. <http://doi.org/10.1002/hep.31288> PMID:32319693
- 625 8. Manning BD, Toker A. AKT/PKB Signaling: Navigating the Network. *Cell.* 2017;169(3):381-405.
626 <http://doi.org/10.1016/j.cell.2017.04.001> PMID:28431241
- 627 9. Sever R, Brugge JS. Signal transduction in cancer. *Csh Perspect Med.* 2015;5(4).
628 <http://doi.org/10.1101/cshperspect.a006098> PMID:25833940
- 629 10. Sun EJ, Wankell M, Palamuthusingam P, McFarlane C, Hebbard L. Targeting the PI3K/Akt/mTOR
630 Pathway in Hepatocellular Carcinoma. *Biomedicines.* 2021;9(11).
631 <http://doi.org/10.3390/biomedicines9111639> PMID:34829868
- 632 11. Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR Signaling in Cancer. *Front Oncol.*
633 2014;4:64. <http://doi.org/10.3389/fonc.2014.00064> PMID:24782981
- 634 12. Yu XN, Chen H, Liu TT, Wu J, Zhu JM, Shen XZ. Targeting the mTOR regulatory network in
635 hepatocellular carcinoma: Are we making headway? *Bba-Rev Cancer.* 2019;1871(2):379-91.
636 <http://doi.org/10.1016/j.bbcan.2019.03.001> PMID:30951815
- 637 13. Yang C, Zhang H, Zhang L, Zhu AX, Bernards R, Qin W, et al. Evolving therapeutic landscape of
638 advanced hepatocellular carcinoma. *Nat Rev Gastro Hepat.* 2023;20(4):203-22.
639 <http://doi.org/10.1038/s41575-022-00704-9> PMID:36369487
- 640 14. Tian LY, Smit DJ, Jucker M. The Role of PI3K/AKT/mTOR Signaling in Hepatocellular
641 Carcinoma Metabolism. *Int J Mol Sci.* 2023;24(3). <http://doi.org/10.3390/ijms24032652> PMID:
642 36768977
- 643 15. Hellwege JN, Velez ED, Acra S, Chen K, Buchowski MS, Edwards TL. Association of gene coding
644 variation and resting metabolic rate in a multi-ethnic sample of children and adults. *Bmc Obes.*
645 2017;4:12. <http://doi.org/10.1186/s40608-017-0145-5> PMID:28417008
- 646 16. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics
647 portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov.*

- 648 2012;2(5):401-4. <http://doi.org/10.1158/2159-8290.CD-12-0095> PMID:22588877
- 649 17. Goldman MJ, Craft B, Hastie M, Repecka K, McDade F, Kamath A, et al. Visualizing and
650 interpreting cancer genomics data via the Xena platform. *Nat Biotechnol.* 2020;38(6):675-8.
651 <http://doi.org/10.1038/s41587-020-0546-8> PMID:32444850
- 652 18. Liao Y, Wang J, Jaehnig EJ, Shi Z, Zhang B. WebGestalt 2019: gene set analysis toolkit with
653 revamped UIs and APIs. *Nucleic Acids Res.* 2019;47(W1): W199-205.
654 <http://doi.org/10.1093/nar/gkz401> PMID:31114916
- 655 19. Slovin S, Carissimo A, Panariello F, Grimaldi A, Bouche V, Gambardella G, et al. Single-Cell RNA
656 Sequencing Analysis: A Step-by-Step Overview. *Methods Mol Biol.* 2021; 2284:343-65.
657 http://doi.org/10.1007/978-1-0716-1307-8_19 PMID:33835452
- 658 20. Hu C, Li T, Xu Y, Zhang X, Li F, Bai J, et al. CellMarker 2.0: an updated database of manually
659 curated cell markers in human/mouse and web tools based on scRNA-seq data. *Nucleic Acids Res.*
660 2023;51(D1):D870-6. <http://doi.org/10.1093/nar/gkac947> PMID:36300619
- 661 21. Qiu X, Mao Q, Tang Y, Wang L, Chawla R, Pliner HA, et al. Reversed graph embedding resolves
662 complex single-cell trajectories. *Nat Methods.* 2017;14(10):979-82.
663 <http://doi.org/10.1038/nmeth.4402> PMID:28825705
- 664 22. Lu Y, Yang A, Quan C, Pan Y, Zhang H, Li Y, et al. A single-cell atlas of the multicellular
665 ecosystem of primary and metastatic hepatocellular carcinoma. *Nat Commun.* 2022;13(1):4594.
666 <http://doi.org/10.1038/s41467-022-32283-3> PMID:35933472
- 667 23. Masoudi M, Seki M, Yazdanparast R, Yachie N, Aburatani H. A genome-scale CRISPR/Cas9
668 knockout screening reveals SH3D21 as a sensitizer for gemcitabine. *Sci Rep-Uk.* 2019;9(1):19188.
669 <http://doi.org/10.1038/s41598-019-55893-2> PMID:31844142
- 670 24. Mossmann D, Park S, Hall MN. mTOR signalling and cellular metabolism are mutual determinants
671 in cancer. *Nat Rev Cancer.* 2018;18(12):744-57. <http://doi.org/10.1038/s41568-018-0074-8>
672 PMID:30425336
- 673 25. Giannone G, Ghisoni E, Genta S, Scotto G, Tuninetti V, Turinetto M, et al. Immuno-Metabolism
674 and Microenvironment in Cancer: Key Players for Immunotherapy. *Int J Mol Sci.* 2020;21(12).
675 <http://doi.org/10.3390/ijms21124414> PMID:32575899
- 676 26. Okkenhaug K. Signaling by the phosphoinositide 3-kinase family in immune cells. *Annu Rev*

- 677 Immunol. 2013;31:675-704. <http://doi.org/10.1146/annurev-immunol-032712-095946>
678 PMID:23330955
- 679 27. Speiser DE, Ho PC, Verdeil G. Regulatory circuits of T cell function in cancer. Nat Rev Immunol.
680 2016;16(10):599-611. <http://doi.org/10.1038/nri.2016.80> PMID:27526640
- 681 28. Tsai CF, Chen GW, Chen YC, Shen CK, Lu DY, Yang LY, et al. Regulatory Effects of Quercetin
682 on M1/M2 Macrophage Polarization and Oxidative/Antioxidative Balance. Nutrients. 2021;14(1).
683 <http://doi.org/10.3390/nu14010067> PMID:35010945
- 684 29. Zhang Q, Lou Y, Bai XL, Liang TB. Immunometabolism: A novel perspective of liver cancer
685 microenvironment and its influence on tumor progression. World J Gastroentero.
686 2018;24(31):3500-12. <http://doi.org/10.3748/wjg.v24.i31.3500> PMID:30131656
- 687 30. Kaneda MM, Messer KS, Ralainirina N, Li H, Leem CJ, Gorjestani S, et al. PI3Kgamma is a
688 molecular switch that controls immune suppression. Nature. 2016;539(7629):437-42.
689 <http://doi.org/10.1038/nature19834> PMID:27642729
- 690 31. Wu X, Chen H, Wang Y, Gu Y. Akt2 Affects Periodontal Inflammation via Altering the M1/M2
691 Ratio. J Dent Res. 2020;99(5):577-87. <http://doi.org/10.1177/0022034520910127> PMID:32228353
- 692 32. Vergadi E, Ieronymaki E, Lyroni K, Vaporidi K, Tsatsanis C. Akt Signaling Pathway in
693 Macrophage Activation and M1/M2 Polarization. J Immunol. 2017;198(3):1006-14.
694 <http://doi.org/10.4049/jimmunol.1601515> PMID:28115590
- 695 33. Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, et al. Functional polarization
696 of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014;513(7519):559-63.
697 <http://doi.org/10.1038/nature13490> PMID:25043024
- 698 34. Sunakawa Y, Stintzing S, Cao S, Heinemann V, Cremolini C, Falcone A, et al. Variations in genes
699 regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based
700 treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials. Ann
701 Oncol. 2015;26(12):2450-6. <http://doi.org/10.1093/annonc/mdv474> PMID:26416897
- 702 35. Xiang X, Wang J, Lu D, Xu X. Targeting tumor-associated macrophages to synergize tumor
703 immunotherapy. Signal Transduct Tar. 2021;6(1):75. <http://doi.org/10.1038/s41392-021-00484-9>
704 PMID: 33619259
- 705